Search research articles
Contact Us
Filters
Showing results (181-190 of 252) with videos related to
Page
of 26
Sort By:
Blood Advances
|
June 10, 2026
Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial
Christof Scheid, Janina Jablonski, Andrea Kerkhoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
Bastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Hemasphere
|
November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
Andreas Engert, Helen Goergen, Jana Markova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Plos One
|
June 13, 2017
Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray
Madlen Loebel, Maren Eckey, Franziska Sotzny, et al.
Blood
|
May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Dennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
JMIR Research Protocols
|
May 26, 2025
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study
Louise Marie Cremer, Ullrich Bethe, Peter Borchmann, et al.
European Journal of Haematology
|
February 19, 2024
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR
Jan-Michel Heger, Yannick d'Hargues, Fanni Kleinert, et al.
International Journal of Cancer
|
November 19, 2013
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma
Achim Rothe, Ron D Jachimowicz, Sven Borchmann, et al.
Blood
|
April 2, 2026
Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial
Anne Sophie Robertz, Ina Bühnen, Julia Meissner, et al.
Page
of 26
Search research articles
Search
Showing results (181-190 of 252) with videos related to
Sort By:
Page
of 26
Blood Advances
|
June 10, 2026
Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial
Christof Scheid, Janina Jablonski, Andrea Kerkhoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial
Bastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Hemasphere
|
November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
Andreas Engert, Helen Goergen, Jana Markova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial
Conrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Plos One
|
June 13, 2017
Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray
Madlen Loebel, Maren Eckey, Franziska Sotzny, et al.
Blood
|
May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Dennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
JMIR Research Protocols
|
May 26, 2025
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study
Louise Marie Cremer, Ullrich Bethe, Peter Borchmann, et al.
European Journal of Haematology
|
February 19, 2024
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR
Jan-Michel Heger, Yannick d'Hargues, Fanni Kleinert, et al.
International Journal of Cancer
|
November 19, 2013
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma
Achim Rothe, Ron D Jachimowicz, Sven Borchmann, et al.
Blood
|
April 2, 2026
Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial
Anne Sophie Robertz, Ina Bühnen, Julia Meissner, et al.
Page
of 26